With a U.S. launch planned for January 2026, the company is focused on ensuring rapid, reliable access to YARTEMLEA. Under a recently announced asset purchase and licensing agreement, Novo Nordisk acquired global rights to zaltenibart (formerly OMS906), a MASP-3 inhibitor in clinical development for PNH and other alternative pathway indications. The company maintains a diversified pipeline including OMS1029, OMS527 for cocaine use disorder, and immuno-oncology programs.
Cyborg Score Rationale
Omeros achieved a major regulatory milestone with FDA approval of its first-in-class YARTEMLEA therapy in December 2025, immediately entering commercialization phase. The company has strengthened its balance sheet through strategic debt restructuring and maintains a robust clinical pipeline spanning complement-mediated diseases, neuropsychiatric disorders, and oncology. However, execution risk remains as the company scales commercial operations for a specialized orphan indication.
Top Insights
FDA-approved lead asset YARTEMLEA launched January 2026, marking transition from development-stage to commercial-stage biotech
Strategic partnership with Novo Nordisk on zaltenibart reduces pipeline risk and generates potential upfront/milestone revenues
Phase 3-ready zaltenibart program addresses larger alternative pathway disorder market (PNH)
Restructured debt maturity profile extends liquidity runway with $230.3M cash position as of mid-2024
Named Competitors
Pegcetacoplan — Alternative pathway complement inhibitor for C3 glomerulopathy and PNH
Iptacopan — Factor B inhibitor for PNH and C3 glomerulopathy
Ultomiris/Pegcetacoplan — Complement C5 inhibitor and alternative pathway targeted therapies
Recent Developments
(December 2025) FDA approval of YARTEMLEA for TA-TMA, first and only lectin pathway inhibitor approved
(December 2025) Announced January 2026 U.S. launch with reimbursement codes established and patient support program
(May 2025) Completed debt restructuring extending maturity on majority of outstanding debt to 2028
(February 2026) Announced completion of nonhuman primate OncotoX-AML study
Open the full interactive Omeros Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.